MNOV · XBRL financial data

Medicinova financial statements, every fiscal year

The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (MNOV's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	—	4,038	—	1,000	—	410
Research and development	7,100	8,100	8,700	5,300	6,800	6,700
General and administrative	6,693	5,715	5,485	5,242	5,481	6,159
Total operating expenses	14,178	14,253	14,629	10,900	12,675	13,693
Operating income (loss)	(14,178)	(10,216)	(14,629)	(9,900)	(12,675)	(13,283)
Other income (expense)	(38)	(59)	(247)	(503)	(39)	(13)
Income tax expense (benefit)	(2)	3	3	3	6	6
Net income (loss)	(13,854)	(10,134)	(14,069)	(8,572)	(11,050)	(11,998)
Earnings per share, basic USD per share	—	(0.21)	(0.29)	(0.17)	(0.23)	(0.24)
Earnings per share, diluted USD per share	—	(0.21)	(0.29)	(0.17)	(0.23)	(0.24)
Weighted average shares, basic thousands of shares	—	48,596	49,045	49,046	49,046	49,063
Weighted average shares, diluted thousands of shares	—	48,596	49,045	49,046	49,046	49,063

Fiscal years (MNOV's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	60,037	71,431	18,505	50,999	40,360	30,806
Short-term investments	—	—	39,982	—	—	—
Accounts receivable	—	—	—	—	0	0
Prepaid and other current assets	680	578	499	175	715	185
Total current assets	60,717	72,009	58,987	51,174	41,074	30,991
Property and equipment, net	56	58	45	46	26	8
Right-of-use asset	171	824	629	575	357	184
Goodwill	9,600	9,600	9,600	9,600	9,600	9,600
Total assets	75,419	87,406	74,155	66,270	55,876	45,603
Accounts payable	617	403	425	1,004	1,102	625
Total current liabilities	2,194	2,833	3,187	3,279	2,959	3,798
Lease liability, non-current	3	695	524	411	211	17
Total liabilities	4,093	3,729	3,913	3,892	3,372	4,016
Accumulated deficit	(382,927)	(393,061)	(407,130)	(415,702)	(426,751)	(438,749)
Total stockholders' equity	71,327	83,677	70,242	62,378	52,504	41,587
Total liabilities and equity	75,419	87,406	74,155	66,270	55,876	45,603
Common shares outstanding (cover page) thousands of shares	48,681	49,043	49,046	49,046	49,046	49,221

Fiscal years (MNOV's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(13,854)	(10,134)	(14,069)	(8,572)	(11,050)	(11,998)
Stock-based compensation	3,176	1,718	643	711	1,192	829
Depreciation and amortization	21	26	18	20	21	20
Net cash from operating activities	(10,826)	(9,382)	(12,912)	(7,431)	(10,643)	(9,810)
Purchases of property and equipment	36	29	5	21	1	3
Net cash from investing activities	(36)	(29)	(40,005)	39,908	(1)	(3)
Proceeds from issuing common stock	—	—	—	—	0	244
Net cash from financing activities	7,106	20,778	8	—	0	244
Net change in cash	(3,756)	11,394	(52,925)	32,494	(10,640)	(9,553)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Medicinova	25,416	458	(1,920)*	49.2M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
Lifevantage	14,920	42,377*	4,767*	12.5M	—	Q4 FY26 10-KJun 30, 2026
Veru	23,880	not reported	(5,467)*	17.1M	4.4 quarters	Q3 FY26 10-QJun 30, 2026
PDS Biotechnology	5,596	not reported	(2,793)*	56.0M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Sutro Biopharma	54,335	9,839	(38,290)*	16.6M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
Whitehawk Therapeutics	85,234	0	(14,529)*	57.0M	13.1 quarters	Q2 FY26 10-QJun 30, 2026
iBio	56,395	0*	(6,228)*	64.3M	14.1 quarters	Q4 FY26 10-KJun 30, 2026
Corbus Pharmaceuticals Holdings	23,370	not reported	(29,626)*	19.3M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
Seres Therapeutics	15,594	736	(22,394)*	9.9M	0.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.